
Noriko Doki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6540235/publications.pdf Version: 2024-02-01



NORKO DOKI

#	Article	IF	CITATIONS
1	Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood, 2015, 125, 1189-1197.	1.4	185
2	Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1183-1189.	2.0	63
3	Postâ€transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for highâ€risk acute myeloid leukaemia. British Journal of Haematology, 2015, 169, 756-759.	2.5	48
4	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 1517-1523.	1.8	48
5	Risk Assessment for Acute Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation Based on Acute Kidney Injury Network Criteria. Internal Medicine, 2012, 51, 2105-2110.	0.7	47
6	Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation. Blood Advances, 2020, 4, 4607-4617.	5.2	42
7	The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Annals of Hematology, 2016, 95, 1145-1150.	1.8	41
8	Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. American Journal of Hematology, 2017, 92, 171-178.	4.1	38
9	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement. Biology of Blood and Marrow Transplantation, 2014, 20, 2029-2033.	2.0	34
10	A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology, 2010, 91, 464-470.	1.6	20
11	Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. Leukemia and Lymphoma, 2016, 57, 76-80.	1.3	19
12	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 2022, 36, 1132-1138.	7.2	16
13	Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 2055-2060.	1.8	11
14	An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 867.e1-867.e9.	1.2	11
15	CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. Leukemia and Lymphoma, 2016, 57, 1375-1381.	1.3	10
16	Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Annals of Hematology, 2018, 97, 73-81.	1.8	10
17	Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2019. 25. 1730-1743.	2.0	10
18	Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1655-1665.	1.8	10

Νογικό Doki

#	Article	IF	CITATIONS
19	Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50Âyears with acute myeloid leukemia in complete remission. Annals of Hematology, 2019, 98, 1799-1801.	1.8	9
20	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 2021, 56, 334-346.	2.4	9
21	Clinical Outcome of Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL): Experience From a Single Institution. Pathology and Oncology Research, 2014, 20, 61-66.	1.9	8
22	A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. International Journal of Hematology, 2015, 102, 460-470.	1.6	8
23	Disseminated nocardiosis after unrelated bone marrow transplantation. Transplant Infectious Disease, 2016, 18, 942-945.	1.7	8
24	Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia. Pathology and Oncology Research, 2017, 23, 433-437.	1.9	8
25	Recipient ADAMTS13 Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy. International Journal of Molecular Sciences, 2019, 20, 214.	4.1	7
26	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2015, 56, 2392-2397.	1.3	6
27	Optic neuritis as an initial manifestation of human herpesvirus 6 reactivation after unrelated bone marrow transplantation. British Journal of Haematology, 2016, 172, 654-654.	2.5	6
28	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Annals of Hematology, 2017, 96, 469-478.	1.8	6
29	Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia. Annals of Hematology, 2020, 99, 147-155.	1.8	6
30	Cyclophosphamideâ€induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120Âmg/kg or less. Asia-Pacific Journal of Clinical Oncology, 2022, , e13674.	1.1	6
31	Essential Roles of the Transcription Factor NR4A1 in Regulatory T Cell Differentiation under the Influence of Immunosuppressants. Journal of Immunology, 2022, 208, 2122-2130.	0.8	6
32	The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. Transplant Immunology, 2017, 42, 34-39.	1.2	5
33	Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 661-664.	2.4	5
34	Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone Marrow Transplantation, 2022, 57, 479-486.	2.4	5
35	Pyomyositis caused by Streptococcus pneumoniae after allogeneic hematopoietic stem cell transplantation. Journal of Infection and Chemotherapy, 2017, 23, 250-252.	1.7	4
36	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	1.4	4

Νογικό Doki

#	Article	IF	CITATIONS
37	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 998-1004.	2.0	4
38	Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1874-1877.	1.3	3
39	Toll - like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. Transplant Immunology, 2016, 38, 60-66.	1.2	3
40	Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 319-321.	1.8	3
41	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapyâ€refractory or relapsed disease prior to allogeneic stem cell transplantation. British Journal of Haematology, 2021, 194, 403-413.	2.5	3
42	The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. Hematological Oncology, 2022, 40, 442-456.	1.7	3
43	Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cytotherapy, 2022, 24, 954-961.	0.7	3
44	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. Cytotherapy, 2022, 24, 1013-1025.	0.7	3
45	Development of aggressive T-cell leukemia at 1 month after the diagnosis of hypereosinophilic syndrome. Leukemia and Lymphoma, 2014, 55, 2402-2404.	1.3	2
46	Toxic encephalopathy after exposure to azacitidine. Leukemia and Lymphoma, 2015, 56, 1538-1539.	1.3	2
47	Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia. International Journal of Hematology, 2019, 109, 1-2.	1.6	2
48	Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200. Annals of Hematology, 2018, 97, 1481-1483.	1.8	1
49	Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions. Transplant Infectious Disease, 2019, 21, e13023.	1.7	1
50	CT of invasive pulmonary aspergillosis (IPA) in cases with hematologic malignancy: Comparison of CT features in the group classified by the severity of neutropenia and underlying disease. European Journal of Radiology, 2020, 131, 109042.	2.6	1
51	Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. International Journal of Hematology, 2021, 114, 263-270.	1.6	1
52	Successful Cord Blood Transplantation for Idiopathic CD4 ⁺ Lymphocytopenia. Acta Haematologica, 2021, 144, 698-705.	1.4	1
53	Donorâ€derived gene mutations in sex chromosome loss after stem cell transplantation. British Journal of Haematology, 2021, 195, e142-e146.	2.5	1
54	Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1873-1882.	1.8	1

Noriko Doki

#	Article	IF	CITATIONS
55	Letter to the Editor: Very low-dose antithymocyte globulin (thymoglobulin) is effective for steroid-refractory acute graft-versus-host disease involving the skin or gut after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2022, 115, 449.	1.6	1
56	Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and Cellular Therapy, 2022, 28, 161.e1-161.e10.	1.2	1
57	Erythrocytosis after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2017, 31, e12918.	1.6	0
58	Sudden blindness as an initial manifestation of localized fusariosis in ethmoid sinus and optic nerve. Annals of Hematology, 2017, 96, 1771-1772.	1.8	0
59	Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFRI². Leukemia and Lymphoma, 2020, 61, 1736-1739.	1.3	0
60	Progressive hepatic cirrhosis early after allogeneic hematopoietic stem cell transplantation in a 5 patient with chronic hepatitis C infection. Turkish Journal of Haematology, 2019, 36, 130-133.	0.5	0
61	The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 2022	1.2	О